- Vasomotor complications are common in men receiving androgen deprivation therapy (ADT) and can be mitigated by pharmacologic and nonpharmacologic strategies.
- There is an increased risk of osteoporosis and skeletal-related events in men receiving ADT. Calcium and vitamin D supplements should be offered to all patients. Osteoclast inhibitors should be considered in men at high risk for osteoporotic fractures and men with metastatic castration-resistant prostate cancer.
- Evidence on the association between ADT use and neurocognitive decline and cardiovascular disease remains mixed and controversial.
- Multidisciplinary management with specialists and allied health professionals may assist in managing the complex side effects of ADT.